Search | Clinical Trials Finder

Conditions: Neovascular (Wet) Age-related Macular Degeneration (AMD)
Interventions: Optical Coherence Tomography; Device
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 50 Years to 100 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Carotid Stenosis
Interventions: Gadobutrol (Gadovist, BAY86-4875); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 479 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 15
States / cities: Tucson, Arizona • Jacksonville, Florida • Savannah, Georgia + 12 more

Conditions: Acute Kidney Injury
Interventions: Angiography; Procedure
Lead sponsor: Tulane University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: New Orleans, Louisiana

Conditions: Endograft Implantation to Repair Abdominal Aortic Aneurysm
Interventions: Contrast Enhanced Ultrasound (Contrast Agent: OptisonTM); Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Cardiovascular Diseases, Myocardial Ischemia, Heart Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Vascular Diseases, Coronary Artery Disease
Interventions: CT(Computed Tomography) guided Percutaneous Coronary Intervention, IVUS (Intravascular Ultrasound) guided Percutaneous Coronary Intervention; Device
Lead sponsor: Fundación EPIC; Other
Eligibility: 18 Years to 85 Years
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 5
States / cities: Boston, Massachusetts • Minneapolis, Minnesota • Jersey City, New Jersey + 1 more

Conditions: Coronary Disease
Interventions: Not listed
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Atherosclerosis
Interventions: Magnetic resonance angiography; Procedure
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Coronary Angiography, Coronary Angioplasty
Interventions: Distal radial artery access, Proximal radial artery surgery; Procedure
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Plano, Texas

Conditions: Retinal Vascular, Normal Eyes
Interventions: OCT Angiography, Color Fundus Photography, Optical Coherence Tomography; Device
Lead sponsor: Heidelberg Engineering GmbH; Industry
Eligibility: 22 Years and older
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Glaucoma
Interventions: Indocyanine Green Angiography, Isocapnic Oxygen, Ocular Imaging with Optical Coherence Tomography (OCT) and Adaptive Optics (AO); Diagnostic Test · Biological
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 88 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Baltimore, Maryland • Silver Spring, Maryland

Conditions: Coronary Disease
Interventions: Not listed
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Coronary Artery Disease, CT
Interventions: CT-guided PCI, Routine PCI; Procedure
Lead sponsor: Minneapolis Heart Institute Foundation; Other
Eligibility: 22 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Vertebrobasilar Insufficiency, Ischemic Attack, Transient, Cerebrovascular Disorder, Brain Ischemia, Stroke
Interventions: Not listed
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 5
States / cities: Los Angeles, California • Chicago, Illinois • St Louis, Missouri + 1 more

Conditions: Coronary Artery Disease
Interventions: Iodixanol, Ioxaglate, Bivalirudin; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Atherosclerosis
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Carotid Stenosis
Interventions: [F-18]RDG-K5; Drug
Lead sponsor: Siemens Molecular Imaging; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Acute Coronary Syndromes, Coronary Artery Disease
Interventions: Not listed
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Sarcoma,Soft Tissue
Interventions: 2% intranasal mupirocin ointment, 4% chlorhexidine gluconate body cleanser; Drug
Lead sponsor: Adam Olson; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Steno-occlusive Disease
Interventions: gadopiclenol, Gadoterate meglumine (Dotarem); Drug
Lead sponsor: Guerbet; Industry
Eligibility: 18 Years and older
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Los Angeles, California • Aurora, Colorado • Evanston, Illinois + 3 more

Conditions: Vascular Disease
Interventions: Not listed
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Coronary Computed Tomographic Angiography, Myocardial Infarction (MI), Cardiac Catheterization
Interventions: GSI Cardiac Scan, Standard of Care CCTA, Research CCTA; Device · Other
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Acute Renal Failure, Kidney Disease, Coronary Artery Disease
Interventions: IV isotonic saline, IV isotonic bicarbonate, N-acetylcysteine, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 5,177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 35
States / cities: Tucson, Arizona • Little Rock, Arkansas • Palo Alto, California + 32 more

Conditions: Breast Cancer, Kidney Neoplasms, Liver Neoplasms
Interventions: contrast agent perflutren lipid, Ultrasound Imaging; Drug · Device
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Coronary Artery Disease (CAD), Renal Impairment, Diabetes Mellitus
Interventions: Iodixanol, Ioversol, Iopromide; Drug
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Princeton, New Jersey

Search by objective public record fields.

OCT Angiography in Wet AMD

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Ultra-Low Contrast Angiography in AKI

Contrast Enhanced Ultrasound vs. Computed Tomographic Angiography in the Detection of Endoleaks Following AAA Repair

A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium (The Optimal Trial)

Evaluate the Effectiveness and Cost of Stress Cardiac Magnetic Resonance Imaging (MRI) for Non-invasive Evaluation of Lesions Discovered on Computed Tomography Angiography (CCTA)

Comparison of Magnetic Resonance Angiography and Standard Angiography in Diagnosing Atherosclerosis

DIstal vs Proximal Radial Artery Access for Cath

Evaluation of the Repeatability and Reproducibility of OCTA Image Quality With the Heidelberg Engineering SPECTRALIS With OCT Angiography Module

Retinal Blood Flow and Autoregulation

Cardiac Computed Tomography In the Management of Patients With indeterminAte or inConclusive Stress Tests

Coronary Computed Tomography Angiography (CCTA) for the Pre-procedural Planning of Percutaneous Coronary Intervention

Vertebrobasilar Flow Evaluation and Risk of Transient Ischemic Attack and Stroke (VERiTAS)

Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography

Magnetic Resonance Angiography (MRA) for the Diagnosis of Atherosclerosis

[F-18] RGD-K5 Positron Emission Tomography (PET) in Participants With Carotid Artery Stenosis

Computed Tomographic Coronary Angiography for Acute Chest Pain Evaluation

Bacterial Decolonization Plus Intraoperative Angiography for Soft Tissue Sarcomas Receiving Preoperative Radiotherapy (CONCERTO)

Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease

Syngo NATIVE Contrast Enhanced 3D MRA on 3T Verio Magnet

GSI Cardiac on Revolution Apex - US

Prevention of Serious Adverse Events Following Angiography

Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging

Renal Effects of Three Iodinated Contrast Media (CM) in Patients at Risk Undergoing Coronary Angiography